Compare KKR & Co Inc (KKR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs BIO-TECHNE Corp — how do they compare? KKR & Co Inc trades at $111.29 (market cap $93.20B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: KKR & Co Inc is far larger — about 8.3× BIO-TECHNE Corp's market cap, and KKR & Co Inc pays the higher dividend (0.75%). Which is the better fit depends on your goals.
| KKR | TECH | |
|---|---|---|
Market Cap | $93.20B | $11.24B |
Sector | Financials | Health |
52-Week High | $149.34 | $72.29 |
52-Week Low | $83.88 | $43.31 |
Enterprise Value | $15.76B | $11.32B |
Dividend Yield | 0.75% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $102.81, down 0.52% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.63 per share, beating estimates, and maintains robust analyst support with a consensus price target of $127.22. Recent news highlights active deal-making, including the acquisition of Integer Holdings and the closing of a $19.2 billion infrastructure fund, signaling growth momentum.
The outlook for KKR is positive, driven by earnings beats, strategic acquisitions, and strong institutional sentiment. Key risks include execution of large deals, market volatility, and interest rate sensitivity. The stock presents an opportunity for growth-oriented investors, supported by a high buy rating consensus and expanding asset management operations.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
